between nedocromil sodium-and cromolyn sodiumtreated groups were noted.
Patients also recorded the number of days missed from work/school/regularly scheduled activities. As shown in Figure 4 , during the 8-week treatment period, 25 patients in the placebo group reported missing one or more days from work/school/regularly scheduled activities. In contrast, only six patients in the nedocromil sodium group missed 1 or more days (p<0.01 compared with placebo). A total of 14 patients treated with cromolyn sodium missed 1 or more days from regularly scheduled activities (p<0.05 compared with placebo).
At the conclusion of the 8-week treatment period, the patients and physicians evaluated the overall effi¬ cacy oftreatment. Both patients and physicians favored the use ofnedocromil sodium or cromolyn sodium over placebo (p^O.OOl). No differences were observed between nedocromil sodium and cromolyn sodium.
Adverse events were collected at each clinic visit during the treatment period. There were no serious side effects reported for any of the three test treat¬ ments. The two most common adverse events were unpleasant taste (nedocromil sodium, 14%; placebo, 4%; cromolyn sodium, 2%) and bronchospasm (nedocromil sodium, 4%; placebo, 12%; and cromolyn sodium, 2%). Table 4 lists the adverse events attributed 
